The Norwegian Structural Biology Centre, Department of Chemistry, UiT The Arctic University of Norway , N-9037 Tromsø, Norway.
Pharmasum Therapeutics AS , Smørblomstvn. 36, N-9102 Kvaløysletta, Norway.
J Med Chem. 2016 Nov 10;59(21):9814-9824. doi: 10.1021/acs.jmedchem.6b01086. Epub 2016 Oct 21.
DYRK1A has emerged as a potential target for therapies of Alzheimer's disease using small molecules. On the basis of the observation of selective DYRK1A inhibition by firefly d-luciferin, we have explored static and dynamic structural properties of fragment sized variants of the benzothiazole scaffold with respect to DYRK1A using X-ray crystallography and NMR techniques. The compounds have excellent ligand efficiencies and show a remarkable diversity of binding modes in dynamic equilibrium. Binding geometries are determined in part by interactions often considered "weak", including "orthogonal multipolar" types represented by, for example, F-CO, sulfur-aromatic, and halogen-aromatic interactions, together with hydrogen bonds that are modulated by variation of electron withdrawing groups. These studies show how the benzothiazole scaffold is highly promising for the development of therapeutic DYRK1A inhibitors. In addition, the subtleties of the binding interactions, including dynamics, show how full structural studies are required to fully interpret the essential physical determinants of binding.
DYRK1A 已成为使用小分子治疗阿尔茨海默病的潜在靶点。基于对萤火虫荧光素选择性 DYRK1A 抑制的观察,我们使用 X 射线晶体学和 NMR 技术研究了苯并噻唑支架的片段大小变体相对于 DYRK1A 的静态和动态结构特性。这些化合物具有优异的配体效率,并在动态平衡中表现出显著的结合模式多样性。结合构象部分由通常被认为是“弱”的相互作用决定,包括“正交多极”类型,例如 F-CO、硫芳基和卤芳基相互作用,以及由电子受主基团变化调制的氢键。这些研究表明,苯并噻唑支架在开发治疗性 DYRK1A 抑制剂方面具有很高的潜力。此外,结合相互作用的细微差别,包括动态,表明如何进行充分的结构研究以充分解释结合的基本物理决定因素。